Sublingual Immunotherapy In Alternaria-Induced Rhinitis

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT01127035
• Date of registration: 19/05/2010
• Primary sponsor: University of Genova
• Public title: Sublingual Immunotherapy In Alternaria-Induced Rhinitis
• Scientific title: STUDIO IN DOPPIO CIECO DISODIOCROMOGLICATO + PLACEBO vs DISODIOCROMOGLICATO + IMMUNOTERAPIA SPECIFICA SUBLINGUALE PER ALTERNARIA IN PAZIENTI CON RINITE ALLERGICA DOVUTA A SENSIBILIZZAZIONE AD ALTERNARIA
• Date of first enrolment: January 2006
• Target sample size: 27
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT01127035
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Countries of recruitment

Italy

Key inclusion & exclusion criteria

Inclusion Criteria:

- Allergic rhinitis

- Symptoms May-October

- Specific IgE to alternaria (skin test/radioallergosorbent [RAST] test)

- Age >14

Exclusion Criteria:

- Sensitization to mites, parietaria, mugwort

- Pregnancy-lactation

- Malignancies

- Chronic systemic steroids

- Previous immunotherapy to alternaria



Age minimum: 14 Years
Age maximum: 65 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Allergic Rhinitis (w/w Asthma) Due to Alternaria Alternata

Intervention(s)

Biological: placebo

Biological: sublingual immunotherapy

Primary Outcome(s)

change in symptom score active versus placebo

Secondary Outcome(s)

change in rescue medication intake

Secondary ID(s)

SLITALT2004

Source(s) of Monetary Support

Please refer to primary and secondary sponsors